The study aimed to explore the accuracy of MR-based tumor radiomics and develop a robust model using a machine learning approach to classify GBM into two distinct molecular subgroups of IDH wild and IDH mutant types in a fairly large cohort of patients. The gene discussed is IDH2; the disease is glioblastoma.